From ECTRIMS 2014, featuring Patricia Cassicia, PhD, discussing research on personalized medicine in MS.
Video credit: National MS Society.
The Future of Personalized Medicine in MS
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...
Mark CompleteCompleted
BookmarkBookmarked
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the ...
Mark CompleteCompleted
BookmarkBookmarked
Ms Nele Handwerker is living with multiple sclerosis (MS), and is a patient advocate. She joins us for World Brain day and shares the story of her MS diagnosis. Nele discusses strategies and resources that she believes could help improve ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Melinda Magyari, EAN 2022: Real-world evidence for disease-modifying therapies in multiple sclerosis
NEW
Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
